Literature DB >> 19122336

Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68.

Ryuichi Kitamura1, Kazuaki Matsuoka, Sekio Nagayama, Masaki Otagiri.   

Abstract

The anti-angiogenic agent TSU-68 is known to rapidly induce cytochrome P450 activity responsible for its own hydroxylation in rats. In this study, we identified CYP1A1 and CYP1A2 as the TSU-68-induced P450 and temporally characterized the rapid induction of these isoforms. Protein and mRNA levels of CYP1A1 and CYP1A2 along with CYP1A activities were examined in rat liver after a single oral administration of 500 mg/kg TSU-68. CYP1A-mediated ethoxyresorufin O-deethylation and TSU-68 hydroxylation activities reached the maximum at 12 hr. The activities were maintained up to 24 hr and then slowly decreased down to control levels. Protein levels of both CYP1A1 and CYP1A2 were also rapidly induced with temporal profiles similar to the profile of CYP1A activity. In contrast, unlike CYP1A2 mRNA levels, which peaked at 12 hr and almost returned to control levels by 48 hr, CYP1A1 mRNA levels peaked as early as 3 hr and returned to control levels by 24 hr. Thus, CYP1A1 showed more rapid elevation and turnover of its mRNA than CYP1A2. In conclusion, TSU-68 administered to rats rapidly induced mRNA and protein of CYP1A1 and CYP1A2 as well as CYP1A activity. Furthermore, the data showed a difference in the time-dependent induction between CYP1A1 and CYP1A2 mRNAs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19122336     DOI: 10.2133/dmpk.23.421

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  4 in total

Review 1.  Sudden infant death syndrome caused by cardiac arrhythmias: only a matter of genes encoding ion channels?

Authors:  Georgia Sarquella-Brugada; Oscar Campuzano; Sergi Cesar; Anna Iglesias; Anna Fernandez; Josep Brugada; Ramon Brugada
Journal:  Int J Legal Med       Date:  2016-02-12       Impact factor: 2.686

2.  A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.

Authors:  Jeeyun Lee; Sang Joon Shin; Ik Joo Chung; Tae Won Kim; Hoo-Geun Chun; Dong Bok Shin; Yeul Hong Kim; Hong Suk Song; Sae-Won Han; Jong Gwang Kim; Sun Young Kim; Young Jin Choi; Hyun Cheol Chung
Journal:  Invest New Drugs       Date:  2014-02-27       Impact factor: 3.850

3.  Commentary: Usage of Mitogen-Activated Protein Kinase Small Molecule Inhibitors: More Than Just Inhibition!

Authors:  Marius Pollet; Jean Krutmann; Thomas Haarmann-Stemmann
Journal:  Front Pharmacol       Date:  2018-08-20       Impact factor: 5.810

4.  In vitro differences in toddalolactone metabolism in various species and its effect on cytochrome P450 expression.

Authors:  Lina Shan; Xianbao Shi; Tingting Hu; Jiayin Hu; Zhe Guo; Yonggui Song; Dan Su; Xiaoyong Zhang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.